Thermo Fisher Scientific Inc. $TMO Shares Acquired by New England Research & Management Inc.

Key Points

• New England Research & Management Inc. has increased its stake in Thermo Fisher Scientific by 28.6% during the second quarter, bringing its total holdings to 2,548 shares valued at $1,033,000.
• Several hedge funds have also expanded their positions in Thermo Fisher, with Mondrian Investment Partners increasing its holdings by 146.1% in the first quarter, now owning 214,506 shares.
• Wall Street analysts have mixed ratings on Thermo Fisher Scientific, with target prices ranging from $480 to $590, and a consensus rating of "Moderate Buy."

New England Research & Management Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,548 shares of the medical research company's stock after purchasing an additional 567 shares during the quarter. New England Research & Management Inc.'s holdings in Thermo Fisher Scientific were worth $1,033,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Mondrian Investment Partners LTD grew its holdings in Thermo Fisher Scientific by 146.1% during the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the period. Advisors Capital Management LLC grew its holdings in Thermo Fisher Scientific by 6.7% during the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after acquiring an additional 7,967 shares during the period. Ilmarinen Mutual Pension Insurance Co grew its holdings in Thermo Fisher Scientific by 5.3% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock worth $33,488,000 after acquiring an additional 3,400 shares during the period. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares in the last quarter. Finally, United Services Automobile Association purchased a new position in Thermo Fisher Scientific in the 1st quarter worth about $4,395,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TMO shares. Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Finally, UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Trading Down 1.0%

NYSE:TMO opened at $474.73 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The business's 50-day moving average price is $467.98 and its two-hundred day moving average price is $450.20. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $179.26 billion, a price-to-earnings ratio of 27.46, a PEG ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.